Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations

NCT03040986 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03040986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03040986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
July 21, 2017
Completion date
October 15, 2020
Enrollment
8 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

kras np_004976.2:p.g12r, stage iii pancreatic cancer ajcc v6 and v7, stage iv pancreatic cancer ajcc v6 and v7